Bain Capital Ventures appointed a former buy platform executive now, pay Affirm later to serve as a new partner.
As TechCrunch reported on Monday, December 6, Christina Melas-Kyriazi will focus her efforts on seed and Series A financing for emerging FinTech and commerce companies, working out of Bain Capital Ventures’ San Francisco office.
“Christina’s expertise at the intersection of fintech and e-commerce is a perfect complement to BCV’s focus on these areas,” said Merritt Hummer, Partner of Bain Capital Ventures, who met with Melas-Kyriazi while they were both studying at Harvard Business School.
Another BCV partner, Matt Harris, adds that the firm has long been looking for someone with expertise in the space where commerce and FinTech intersect.
Matt Harris, a partner at Bain Capital Ventures, agrees, saying his company has “been looking for a long time” for someone familiar with the intersection of FinTech and commerce.
“More than half of our investments are in these two categories,” Harris told the outlet. “And what we’ve found is that some of the best companies don’t fit neatly into a category. They are often halfway between two activities.
In addition to her time with Affirm, Melas-Kyriazi was an angel investor, a road that led her to BCV, she says.
“The switch to VC was a natural transition,” she said. “There are still so many difficult issues to solve, especially in fintech and commerce technology, and I’m excited to continue working with great founders and supporting the next generation of mission-driven fintech founders. “
Read more: Socure Raises $ 450 Million at $ 4.5 Billion Valuation in Oversubscribed Series E
BCV says Melas-Kyriazi’s arrival comes at a time of expansion for the company, which raised $ 1.3 billion earlier this year and as part of a new focus on funding for priming and series A.
This does not mean that BCV only pursues this type of offer. Last month, the company was one of the new investors in a $ 450 million Series E round on the digital identity and fraud verification platform Socure, which valued the company at 4.5. billions of dollars.